Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma.

Andrew X Zhu Farshid DayyaniChia-Jui YenZhenggang RenYuxian BaiZhiqiang MengHongming PanPaul Dillon Shivani K MhatreVincent E GaillardSairy HernandezRobin Kate Kelley Bruno Sangro

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

AFP response at 6 weeks after initiating treatment is a potential surrogate biomarker of prognosis for patients with HCC receiving atezolizumab + bevacizumab. See related commentary by Cappuyns and Llovet, p. 3405.

Keyphrases

risk assessment
drug induced